Repligen ( (RGEN) ) has provided an announcement.
Repligen Corporation reported a robust third quarter of 2024, with a 10% increase in revenue to $155 million year-over-year. The company experienced significant growth in the CDMO segment and equipment sales, each up by approximately 20%, and announced the acquisition of chromatography innovator Tantti Laboratory Inc. Repligen also opened a new Training and Innovation Center, enhancing its bioprocessing technology showcase. The adjusted net income reached $24 million, with a positive outlook for the upcoming year.
For detailed information about RGEN stock, go to TipRanks’ Stock Analysis page.
